Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results and take investor questions.
Investors may submit questions by email to investorrelations@etonpharma.com. The live webcast and a 30-day archive will be available in the Investors section of Eton’s website at https://ir.etonpharma.com/.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Earnings date | Neutral | +0.7% | Announced first-quarter 2026 results date and conference call schedule |
| Mar 03 | Earnings date | Neutral | +0.5% | Announced fourth-quarter and full-year 2025 results date and webcast schedule |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Both prior earnings-date announcements were followed by positive 24-hour price reactions despite the announcements providing scheduling information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
| Participant Call Link: | Click Here | |
| Webcast: | Click Here | |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eleven commercial rare disease products: KHINDIVI®, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, IMPAVIDO®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
